President Trump’s critical comments on China triggered a market sell-off, fueled by concerns over worsening trade relations. China’s export controls on rare earth minerals heightened tensions, leading to fears of supply chain disruptions and increased costs for technology companies. Among impacted stocks, Collegium Pharmaceutical saw a significant move, up 11.8% YTD but still below its 52-week high. Investors who bought shares 5 years ago would see a 47.5% return. As the market reacts to news, opportunities may arise to buy quality stocks. Additionally, emerging enterprise software stocks leveraging AI capabilities could be the Gorillas of the future.

Read more at StockStory: UnitedHealth, Brookdale, Collegium Pharmaceutical, QuidelOrtho, and Biogen Shares Are Falling, What You Need To Know